^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CyPep-1

    i
    Other names: CyPep-1, CY-101
    Associations

    News

    Trials
    Company:
    Cytovation
    Drug class:
    Immunomodulator, Axin2 activator
    Related drugs:
    Associations

    News

    Trials
    2ms
    Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
    P1/2, N=6, Completed, Cytovation AS | Active, not recruiting --> Completed | N=90 --> 6 | Trial completion date: Feb 2025 --> Sep 2024
    Trial completion • Enrollment change • Trial completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • CyPep-1
    4ms
    CICILIA: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (clinicaltrials.gov)
    P1/2, N=60, Completed, Cytovation AS | Active, not recruiting --> Completed | Trial primary completion date: Mar 2024 --> Jul 2024
    Trial completion • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    Keytruda (pembrolizumab) • CyPep-1
    11ms
    Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
    P1/2, N=90, Active, not recruiting, Cytovation AS
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • CyPep-1
    1year
    Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
    P1/2, N=90, Active, not recruiting, Cytovation AS | Recruiting --> Active, not recruiting | Phase classification: P1b/2a --> P1/2
    Enrollment closed • Phase classification • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • CyPep-1
    1year
    CICILIA: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (clinicaltrials.gov)
    P1/2, N=75, Active, not recruiting, Cytovation AS | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Jul 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • CyPep-1
    over1year
    Catalyst: A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers (clinicaltrials.gov)
    P1b/2a, N=90, Recruiting, Cytovation AS | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • CyPep-1
    2years
    A study to evaluate the safety and efficacy of CyPep-1 in combination with Pembrolizumab for the treatment of advanced or metastatic cancers. (clinicaltrialsregister.eu)
    P1/2, N=90, Ongoing, Cytovation ASA
    New P1/2 trial • Combination therapy
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • CyPep-1
    2years
    CICILIA: CyPep-1 Injections in Cancer Inducing Lymphocyte Infiltrate Accumulations (clinicaltrials.gov)
    P1/2, N=75, Recruiting, Cytovation AS | N=45 --> 75 | Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Aug 2022 --> Aug 2023
    Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation
    |
    Keytruda (pembrolizumab) • CyPep-1